Chemours CO 8-K filings

The Chemours Company has entered into a consent decree with the EPA and WVDEP to resolve PFAS-related environmental claims across three major manufacturing facilities.

The Chemours Company reported Q1 2026 net sales of $1.4 billion, bolstered by record Thermal & Specialized Solutions performance despite operational headwinds in other segments.

The Chemours Company completed a private offering of $700 million in 7.875% senior unsecured notes due 2034 to refinance existing debt.

The Chemours Company successfully upsized and priced a private offering of $700 million in 7.875% senior unsecured notes due 2034 to refinance existing debt.

Chemours reports mixed Q4 and full year 2025 results, with strong Opteon Refrigerants growth in TSS offsetting headwinds in other segments, while providing a positive 2026 outlook.

The Chemours Company announced the sale of its former titanium dioxide manufacturing site in Kuan Yin, Taiwan, for approximately $360 million, with proceeds earmarked for debt reduction.

The Chemours Company reported flat net sales in Q3 2025, with strong Opteon refrigerant demand offsetting weakness in other segments and operational disruptions.

The Chemours Company's Board of Directors has adopted a new executive severance policy to enhance retention and stability among senior management.

The Chemours Company announced a significant debt maturity extension for its $1.05 billion term loan and established a new €180 million receivables purchase agreement to enhance liquidity.

The Chemours Company announced the appointment of Mary Cranston as Chair of the Board and Alister Cowan as Lead Independent Director, effective September 2, 2025.

The Chemours Company's Board Chair, Dawn Farrell, is resigning to lead a new Canadian government initiative, with a successor yet to be named.

Chemours reported strong second-quarter 2025 Adjusted EBITDA and sales growth driven by Opteon refrigerants, despite a significant GAAP net loss due to a $257 million PFAS litigation settlement with New Jersey.

Chemours, DuPont, and Corteva have reached an $875 million settlement with the State of New Jersey to resolve all pending environmental and PFAS-related claims across four operating sites and statewide.

Chemours' Q1 2025 results show flat sales year-over-year but a decline in net income, driven by restructuring charges and pricing pressures, while the company progresses with its 'Pathway to Thrive' strategy.

The Chemours Company held its annual meeting on April 22, 2025, where shareholders elected directors, approved executive compensation on an advisory basis, ratified the selection of PricewaterhouseCoopers LLP, and voted on amendments to the company's certificate of incorporation and a shareholder proposal.

The Chemours Company amended its receivables purchase agreement, extending the maturity date to March 31, 2028, and decreasing the facility limit to $165 million.

Guillaume Pepy will not seek re-election to The Chemours Company's Board of Directors at the 2025 Annual Meeting.

Curtis V. Anastasio will not seek re-election to The Chemours Company's Board of Directors at the 2025 Annual Meeting.

Chemours announced its Q4 and full year 2024 financial results, highlighting a new strategic direction and mixed performance across its business segments.

Chemours appoints Leslie M. Turner to its Board of Directors, effective February 19, 2025, and announces the 2025 Annual Meeting of Shareholders will be held on April 22, 2025.

The Chemours Company has appointed Joseph Kava, a Google executive with extensive technology experience, to its Board of Directors, effective January 3, 2025.

Chemours has successfully repriced its 415 million Euro term loan, reducing the interest rate margin.

The Chemours Company filed an amendment to its previous 8-K report to correct a technical error related to exhibits for its $600 million senior notes offering.

Chemours has successfully repriced its $1.07 billion term loan, reducing interest rate margins and potentially lowering borrowing costs.

Chemours has successfully closed a private offering of $600 million in senior unsecured notes due in 2033, with proceeds primarily intended to redeem existing euro-denominated notes.

Chemours has launched a private offering of $600 million in senior unsecured notes due 2033, primarily to redeem existing euro-denominated debt.

Chemours announced its third quarter 2024 financial results, highlighted by record sales in its Thermal & Specialized Solutions segment, while also outlining a refreshed corporate strategy.

Chemours' August 2024 investor presentation outlines the company's strategic focus on growth in advanced materials, thermal solutions, and titanium technologies, alongside sustainability efforts.

Chemours' second quarter results show a year-over-year decrease in sales and adjusted EBITDA, but a significant improvement in net income compared to the prior year.

The Chemours Company has appointed David A. Will as its new Controller and Chief Accounting Officer, effective August 12, 2024.